Ranibizumab Treatment for Retinal Angiomatous Proliferation Lesions: A Case Report with Life-Long Expectancy (Seven Years) Follow-Up

G. Donati; C. J. Pournaras

doi:10.1055/s-0034-1396332

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2015; 232(4): 570-572
DOI: 10.1055/s-0034-1396332

Der interessante Fall

Georg Thieme Verlag KG Stuttgart · New York

Ranibizumab Treatment for Retinal Angiomatous Proliferation Lesions: A Case Report with Life-Long Expectancy (Seven Years) Follow-Up

Ranibizumab in der Behandlung retinaler angiomatöser Proliferations Läsionen: Eine Fallstudie mit langer Lebenserwartung (verfolgt über sieben Jahre)

Authors

G. Donati

¹Department of Ophthalmology, University Hospitals of Geneva, Geneva, Switzerland

²Centre Ophtalmologique de Rive, Geneva, Switzerland

³Centre Ophtalmologique de La Colline, Clinique La Colline, Geneva, Switzerland
C. J. Pournaras

²Centre Ophtalmologique de Rive, Geneva, Switzerland

³Centre Ophtalmologique de La Colline, Clinique La Colline, Geneva, Switzerland

Abstract

Full Text

References

References
1 Yannuzzi LA, Freund KB, Takahashi BS et al. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina 2008; 28: 375-384
2 Parodi MB, Iacono P, Menchini F et al. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol 2013; 91: 267-273
3 Mones J, Biarnés M, Badal J. Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report. Clin Ophthalmol 2013; 7: 1089-1092
4 Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444
5 Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
6 Rouvas AA, Chatziralli IP, Theodossiadis PG et al. Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation. Retina 2012; 32: 1181-1189
7 Inoue M, Arakawa A, Yamane S et al. Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life. Clin Ophthalmol 2014; 8: 1711-1716
8 Bandello F, Lafuma A, Berdeaux G. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest Ophthalmol Vis Sci 2007; 48: 96-103
9 Rofagha S, Bhisitkul RB, Boyer DS et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120: 2292-2299